MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ
2.940
-0.210
-6.67%
After Hours: 2.960 +0.02 +0.68% 19:59 03/27 EDT
OPEN
3.090
PREV CLOSE
3.150
HIGH
3.120
LOW
2.910
VOLUME
19.29M
TURNOVER
--
52 WEEK HIGH
7.18
52 WEEK LOW
2.910
MARKET CAP
1.55B
P/E (TTM)
-2.0403
1D
5D
1M
3M
1Y
5Y
1D
Recursion Pharmaceuticals Names New Chief Medical Officer
TipRanks · 4d ago
Recursion Pharmaceuticals director Christopher Gibson drops 40,000 common shares; disposal totals $130,000
Reuters · 4d ago
New Recursion CMO Puts Oncology Experience At Center Of Investor Focus
Simply Wall St · 4d ago
Recursion names Vicki Goodman as CMO
Seeking Alpha · 4d ago
Recursion Pharmaceuticals announces Vicki Goodman as chief medical officer
TipRanks · 4d ago
Recursion names Vicki Goodman chief medical officer effective April 6, 2026; David Mauro exits after about three years
Reuters · 4d ago
RECURSION PHARMACEUTICALS INC - APPOINTS VICKI GOODMAN AS CHIEF MEDICAL OFFICER EFFECTIVE APRIL 6, 2026
Reuters · 4d ago
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Prolonged Share Price Weakness
Simply Wall St · 6d ago
More
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

Webull offers Recursion Pharmaceuticals Inc stock information, including NASDAQ: RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.